Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer

Table 1 Baseline characteristics, n (%)

Variable	All (63)	Excellent efficacy group (42)	Poor efficacy group (21)
Age	56 (51, 58)	56 (50, 58)	59 (50, 62)
Sex
Male	34 (54.7)	20 (47.6)	14 (66.7)
Female	29 (45.3)	22 (52.4)	7 (33.3)
ECOG-PS
0	17 (27.0)	12 (28.6)	5 (23.8))
1	39 (61.9)	26 (61.9)	13 (61.9)
2	7 (11.1)	4 (9.5)	3 (14.3)
Disease status
Unresectable	55 (87.3)	38 (90.5)	17 (81.0)
Recurrent	8 (12.7)	4 (9.5)	4 (19.0)
Number of organs involved
1	40 (63.5)	27 (64.3)	13 (61.9)
≥ 2	23 (36.5)	15 (35.7)	8 (38.1)
HER2 status
0	31 (49.2)	17 (40.5)	14 (66.7)
1	15 (23.8)	10 (23.8)	5 (23.8)
2	11 (17.5)	11 (26.2)	0 (0)
Unmeasured	6 (9.5)	4 (9.5)	2 (9.5)
CPS
0	8 (12.7)	2 (4.8)	6 (28.6)
1 ≤ CPS < 5	11 (17.5)	7 (16.7)	4 (19.0)
5 ≤ CPS < 10	12 (19.0)	9 (21.4)	3 (14.3)
CPS ≥ 10	21 (33.3)	18 (42.9)	3 (14.3)
Unmeasured	11 (17.5)	6 (14.3)	5 (23.8)
EBER
Positive	7 (11.1)	6 (14.3)	1 (4.8)
Negative	42 (66.7)	26 (61.9)	16 (76.2)
Unmeasured	14 (22.2)	10 (23.8)	4 (19.0)

ECOG-PS: Eastern cooperative oncology group-performance status; CPS: Combined positive score; HER2: Human epidermal growth factor receptor 2; EBER: Epstein-Barr virus-encoded small RNA.